Large pharma companies consider R&D such a defining capability, they've been hesitant to move these activities outside the firm-much less offshore. This paper addresses new market forces that are compelling them to consider a range of alternatives, including outsourcing and offshore opportunities.
- Vendor:
- IBM Line of Business
- Posted:
- Feb 8, 2021
- Published:
- Sep 1, 2006
- Format:
- PDF
- Type:
- White Paper
